Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma

Autor: Lauren B. Smith, Mark S. Kaminski, Anca M. Avram, Scott J. Wilderman, Yuni K. Dewaraja, Peter L. Roberson, Meredith A. Morgan, Matthew J. Schipper
Rok vydání: 2017
Předmět:
Adult
Male
Patient-Specific Modeling
Cancer Research
medicine.medical_treatment
Disease-Free Survival
030218 nuclear medicine & medical imaging
03 medical and health sciences
0302 clinical medicine
immune system diseases
hemic and lymphatic diseases
Dose prediction
Biomarkers
Tumor
medicine
Humans
Dosimetry
Radiology
Nuclear Medicine and imaging
Radiosensitivity
Aged
Aged
80 and over
Tomography
Emission-Computed
Single-Photon
Pharmacology
medicine.diagnostic_test
business.industry
Lymphoma
Non-Hodgkin
Radiotherapy Planning
Computer-Assisted
Dose-Response Relationship
Radiation
Radiotherapy Dosage
Original Articles
General Medicine
Middle Aged
Radioimmunotherapy
medicine.disease
Lymphoma
Treatment Outcome
Oncology
Positron emission tomography
030220 oncology & carcinogenesis
Biomarker (medicine)
Female
Tomography
X-Ray Computed
Nuclear medicine
business
Emission computed tomography
Zdroj: Cancer Biotherapy and Radiopharmaceuticals. 32:309-319
ISSN: 1557-8852
1084-9785
Popis: Non-Hodgkin Lymphoma patients respond differently to therapy according to inherent biological variations. Pretherapy biomarkers may improve dose-response prediction.Hybrid single-photon emission computed tomography (SPECT)/computed tomography (CT) three-dimensional imaging at multiple time points plus follow-up positron emission tomography (PET)/CT or CT at 2 and 6 months post therapy were used to fit tumor response to combined biological effect and cell clearance models from which three biological effect response parameters (radiosensitivity, cold effect sensitivity, and proliferation potential) were determined per patient. A correlation of biological effect parameters and pretherapy biomarker data (ki67, p53, and phospho-histone H3) allowed a dose-based equivalent biological effect (EBE) to be calculated for each patient.Significant correlations were found between biological effect parameters and pretherapy biomarkers. Optimum correlations were found by splitting the patient data according to p53 status. Response correlation of progression free survival (PFS) and EBE were significantly improved compared with PFS and absorbed dose alone.It is possible and desirable to use pretherapy biomarkers to enhance the predictive potential of dose calculations for patient-specific treatment planning.
Databáze: OpenAIRE
Externí odkaz: